x

Posted 02 March, 2023

Oncocyte Corp appointed Joshua Riggs as new CEO

Nasdaq:OCX appointed new Chief Executive Officer Joshua Riggs in a 8-K filed on 02 March, 2023.


  Effective February 24, 2023, the Board of Directors of Oncocyte Corporation ("Oncocyte" or the "Company") appointed Joshua Riggs as Chief Executive Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Oncocyte Corp
Health Care/Life Sciences • Biotechnology
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Market Cap
$24.8M
View Company Details
Oncocyte Corp by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective February 24, 2023, the Board of Directors of Oncocyte Corporation ("Oncocyte" or the "Company") appointed Joshua Riggs as Chief Executive Officer of the Company. Mr. Riggs has also been appointed President and joined the Company's Board of Directors effective February 28, 2023. The compensation of Mr. Riggs was previously disclosed in a Form 8-K filed with the Securities and Exchange Commission on December 5, 2022.


Mr. Riggs, age 40, has served as the Company's Interim Chief Executive Officer since December 2022. Mr. Riggs previously served as the Company's General Manager, Transplant from July 2022, and the Company's Senior Director Business Development from August 2020 until September 2022. From January 2015 to August 2020, Mr. Riggs was the founder and principal of Intelliger Consulting, an organization devoted to consumer driven healthcare, and from January 2016 to July 2020, he was a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.


There have been no transactions with Oncocyte and there are currently no proposed transactions with Oncocyte that would require disclosure under Item 404(a) of Regulation S-K. No arrangement or understanding exists between Mr. Riggs and any other person pursuant to which Mr. Riggs was selected as an officer of the Company. No "family relationship," as that term is defined in Item 401(d) of Regulation S-K, exists between Riggs, on the one hand, and any of the Company's directors or executive officers, on the other hand.